

Sawai Pharmaceutical Launches Seven Compounds with 17 Strengths of Generic Drugs

Osaka, Japan – June 14, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of seven compounds with 17 strengths of generic drugs. Sawai's product line now includes 302 compounds with 738 strengths.

The list of new products:

1. ILUAMIX® Combination Tablets LD [SAWAI] / HD [SAWAI]




- Generic name: Irbesartan / Amlodipine Besilate
- Indications: Hypertension
- Brand products: AIMIX® Combination Tablets LD / HD

2. Bepotastine Besilate OD Tablets 5 mg [SAWAI] / 10 mg [SAWAI], Bepotastine Besilate Tablets 5 mg [SAWAI] / 10 mg [SAWAI]



- Generic name: Bepotastine Besilate
- Indications: Allergic rhinitis, urticaria, and pruritus associated with dermatitis (eczema/skin inflammation, prurigo, pruritus cutaneous)
- Brand products: TALION® OD Tablets 5 mg / 10mg, TALION® Tablets 5 mg / 10 mg

3. Minodronic Acid Tablets 1 mg [SAWAI] / 50 mg [SAWAI]




- Generic name: Minodronic Acid Hydrate
- Indications: Osteoporosis
- Brand products: Bonoteo® Tablets 1 mg / 50 mg, RECALBON® Tablets 1 mg / 50mg

- **Striking features:** To promote proper use of the product and for patients' convenience, the instruction card is applied directly to the blister pack. This special feature is being used for the first time in the Japanese generics industry. This package is a patient friendly design. Folding the instruction card in half allows the patient to remove the tablet easily from the blister pack. Dosage and administration instructions are prominently displayed as this drug is directed to be taken as 1 tablet at a time once every 4 weeks.




4. Lamotrigine Tablets 25 mg [SAWAI] / 100 mg [SAWAI], Lamotrigine Tablets for Pediatric 2 mg [SAWAI] / 5 mg [SAWAI]



- Generic name: Lamotrigine
- Indications:
 - Monotherapy for the following seizures in patients with epilepsy
 - partial-onset seizures
 - tonic-clonic seizures
 - Adjunctive therapy for the following seizures in patients not having obtained sufficient efficacy with other antiepileptic drugs
 - partial seizures
 - tonic-clonic seizures
 - generalized seizures associated with Lennox-Gastaut syndrome
 - Suppression of recurrent/relapsed mood episode in patients with bipolar disorder
- Brand products: Lamictal® Tablets 25 mg / 100 mg, Lamictal® Tablets For Pediatric 2 mg / 5 mg

5. Nalfurafine Hydrochloride OD Tablets 2.5 µg [SAWAI]



- Generic name: Nalfurafine Hydrochloride
- Indications: Improvement of pruritus in the hemodialysis patients (use only when sufficient efficacy is not obtained with the existing therapies or treatments):
- Brand products: REMITCH® OD Tablets 2.5 µg / Capsules 2.5 µg
NOPICOR® Capsules 2.5 µg
- **Striking features:** Since water intake is sometimes restricted for dialysis patients Sawai aimed to reduce the dose burden of patients by developing OD tablets which can be taken without water.

6. Lanthanum Carbonate Granules Sachet 250 mg [SAWAI] / 500 mg [SAWAI]




- Generic name: Lanthanum carbonate hydrate
- Indications: Improvement of hyperphosphatemia in patients with chronic kidney disease
- Brand products: Fosrenol® Granules Sachet 250 mg / 500 mg

7. Oseltamivir Capsules 75 mg [SAWAI] / DS 3% [SAWAI]



- Generic name: Oseltamivir phosphate
- Indications: Treatment or prophylaxis of influenza type A or B virus infection
- Brand products: TAMIFLU® Capsules 75 / Dry Syrup 3%
- **Striking features:** TAMIFLU plays an important role in preparation for an influenza pandemic. Only Sawai is able to launch this product.

A special feature of packages:



Product name is visible even when the lid of the box is opened.

This feature supports [recommendations by] medical experts to easily confirm the product name when returning the blister packs to the box.

These products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

◆ Contact Information ◆

PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.

E-mail: koho@sawai.co.jp